Artificial intelligence (AI) is rapidly changing modern medicine, with radiology at the heart of its transformation. From automatic image analysis to workflow optimization, AI promises faster diagnoses, reduced burnout, and improved access to imaging services. These tools, however, need to be developed and advanced within strong ethical frameworks. Radiologists, trainees, and other stakeholders must work together to address new questions of responsibility, fairness, and oversight in this fast-evolving landscape.
This article examines the ethical implications of AI in radiology, including concerns around decision-making, transparency, and bias, and advocates for regulations and collaborative oversight to ensure responsible integration into clinical practice.
AI has already demonstrated remarkable capabilities in identifying abnormalities in imaging, triaging imaging studies, and generating automated radiology reports. In some instances, such as detecting lung nodules, AI has demonstrated sensitivity equal to or exceeding that of radiologists, with recent studies showing that newer algorithms can achieve high sensitivity while also reducing false positives (Khalaji et al., 2025).
At the same time, the power of AI poses ethical concerns. How can we ensure that these tools are safe, fair, and transparent? When an AI tool recommends a diagnosis, is the radiologist, the AI developer, or the institution accountable? These are foundational issues that involve the core of accountability, medical ethics, and professionalism.
As AI systems become more autonomous, radiologists may be tempted to rely too heavily on them for reading studies and clinical decision-making. But ethical practice calls for radiologists to retain ultimate responsibility for diagnoses and patient care recommendations. In other words, ethical use of AI should augment human expertise rather than replace it.
Both the American College of Radiology (ACR) and the European Society of Radiology (ESR) emphasize that AI tools must be explainable, verifiable, and used under appropriate clinical oversight (Geis et al., 2019; ESR, 2019). The future of medicine is not about replacing clinicians with machines but about facilitating collaboration in which AI’s abilities complement clinical judgment.
Additionally, delegating clinical judgment to AI tools without a full understanding of their training data, performance metrics, and potential points of failure can be dangerous. Radiologists should be educated on the full spectrum of AI’s limitations, biases, and legal and ethical implications, in addition to its clinical use.
One of the most pressing ethical issues in AI implementation is bias. AI models trained on non-representative datasets have limited external validity and may perform poorly on underserved or marginalized populations. For example, if an AI tool is developed using predominantly white, urban, insured patient populations, it may fail to detect disease accurately in patients from rural, low-income, or racially diverse backgrounds.
Addressing these disparities requires that AI tools be designed and validated with consideration of diversity and inclusion. Continuous performance monitoring, data analysis, and transparency in training data are essential to minimizing health inequities caused by algorithmic bias.
As AI tools are integrated into clinical workflows, patients may not even be aware that AI is playing a role in their care. This raises questions about informed consent. Should patients be notified when AI is used to interpret their imaging? Should the consent process include discussion of potential risks, limitations, or the use of patient data in algorithm training?
While the answers to these questions are still developing, a key principle is that patients deserve transparency. Communication in terms that patients can understand, including how AI is used, helps preserve trust and shared decision-making between clinicians and patients.
As AI continues to advance, the rules that govern its use in medicine need to keep pace. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) now classify many AI tools as medical devices (EMA, 2023; U.S. FDA, 2021). Some of these systems are “locked,” meaning their parameters never change, while others are “adaptive,” learning from new data even after they are rolled out (U.S. FDA, 2021). Adaptive systems offer exciting possibilities but raise concerns about oversight and safety.
In 2021, the FDA released its Artificial Intelligence and Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan, which remains the backbone of current regulation (U.S. FDA, 2021). The plan highlighted five priorities: allowing some pre-approved algorithm changes through Predetermined Change Control Plans (PCCPs), creating Good Machine Learning Practices (GMLP), improving transparency with patients, strengthening real-world monitoring, and encouraging collaboration among regulators, developers, and researchers (U.S. FDA, 2021).
Since then, the FDA has expanded its approach to what it calls the Total Product Lifecycle (TPLC), which stresses the need for ongoing monitoring even after approval (U.S. FDA, 2021). This is especially important for adaptive AI. Imagine a tool approved to detect lung nodules that eventually learns to also flag signs of early malignancy (Khalaji et al., 2025). While that does sound like a positive progression, without proper oversight, it could lead to unnecessary testing, more false positive results, or even missed errors.
To help address this, the FDA formally established PCCPs in 2025. These plans require developers to spell out what kinds of changes are expected, how those changes will be validated, and how they will affect safety and performance (U.S. FDA, 2025). Still, PCCPs are limited as they apply only to anticipated changes and do not monitor AI in real time (U.S. FDA, 2024). Truly adaptive systems will require stricter regulations, including real-time tools to detect and validate evolutionary changes in AI behavior. Without such measures, there is a real risk that AI will evolve beyond its approved scope (U.S. FDA, 2025).
The FDA has also worked on broader issues such as algorithmic bias, interpretability, and patient safety (U.S. FDA, 2024). Through public workshops and partnerships with groups like the International Medical Device Regulators Forum, the agency has emphasized that human input and accountability are crucial, even as these AI systems become more advanced (U.S. FDA, 2024).
Medical students and residents must be prepared to use this new advancement. This includes understanding how AI tools work and assessing their appropriateness, limitations, and ethical implications. Incorporating AI-related governance, data literacy, and medical ethics into radiology education ensures trainees and practicing radiologists stay up to date on the latest standards for responsible practice.
Organizations like the American College of Radiology (ACR) and the Radiological Society of North America (RSNA) are offering more resources and educational opportunities on AI. Still, more can be done to empower today’s medical students and residents to take an active role in these discussions, as many have grown up with advanced technology and often possess a solid foundation in AI. This presents a unique opportunity to engage and educate the next generation of radiologists from the ground up.
The integration of AI into radiology offers unbelievable potential, but without ethical considerations, that potential may come at the cost of transparency, equity, and accountability. As we advance further down this path, we should consider the following questions:
Answering these questions will require multidisciplinary teamwork, diverse perspectives, and a shared commitment to using AI responsibly. Moving forward, the key will be balancing AI innovation with ethical responsibility, keeping patient safety and trust central to every decision. As a student, I am excited about the potential AI brings to radiology and motivated to contribute to its ethical integration into patient care.
What Radiology Can Learn
Discover how radiology AI can learn from ophthalmology, dermatology, and pathology to improve trust, reduce bias, streamline workflows, and enable learning.
Read more
How Theranostics Is Redefining Radiology
Theranostics is transforming radiology from scan interpretation to precision treatment, enabling radiologists to diagnose, target and treat disease.
Read more
The Next Chapter in Radiology Informatics
ACR informatics takes a long-term, collaborative approach, advancing AI, interoperability, and practical tools to improve radiology workflows and patient care.
Read more
